13G Filing: Billionaire Andreas Halvorsen Adds to Stake in Kite Pharma, Inc. (KITE)

Kite Pharma Inc (NASDAQ:KITE) is the subject of a new 13G filing issued by Andreas Halvorsen‘s Viking Global. The filing shows that the billionaire Tiger Cub has buffed his stake in the company to 2.44 million shares, up from 2.21 million shares at the end of 2015, when Viking Global owned the second-largest position in the stock among investors in our database. The current position now amasses an even 5.0% of the company’s stock. The full content of the filing can be found below.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Viking Global Investors 0 2,441,232 0 2,441,232 2,441,232 5.0%
Viking Global Performance 0 1,648,367 0 1,648,367 1,648,367 3.4%
Viking Global Equities 0 562,091 0 562,091 562,091 1.2%
Viking Global Equities II 0 32,967 0 32,967 32,967 0.1%
VGE III Portfolio Ltd 0 1,053,309 0 1,053,309 1,053,309 2.2%
Viking Long Fund GP 0 616,489 0 616,489 616,489 1.3%
Viking Long Fund Master Ltd 0 616,489 0 616,489 616,489 1.3%
Viking Global Opportunities GP 0 176,376 0 176,376 176,376 0.4%
Viking Global Opportunities Portfolio GP 0 176,376 0 176,376 176,376 0.4%
Viking Global Opportunities Liquid Portfolio Sub-Master 0 176,376 0 176,376 176,376 0.4%
O. Andreas Halvorsen 0 2,441,232 0 2,441,232 2,441,232 5.0%
David C. Ott 0 2,441,232 0 2,441,232 2,441,232 5.0%
Daniel S. Sundheim 0 2,441,232 0 2,441,232 2,441,232 5.0%
Andreas Halvorsen
Andreas Halvorsen
Viking Global

Page 1 of 20 SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________

Schedule 13G
________________

INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c)
AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934*

Kite Pharma, Inc.
(Name of Issuer)

Common Stock, par value $0.001 per share
(Title of Class of Securities)

49803L109
(CUSIP Number)

February 18, 2016
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)

___________

* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

Follow Kite Pharma Inc. (NASDAQ:KITE)